Image source: shutterstock

Highlights

  • FY27 Margin Target: Healius aims for a high single-digit EBIT margin, surpassing Citi and Jefferies' estimates.

  • Analyst Reactions: Citi remains skeptical due to past performance, while Jefferies sees potential but awaits execution.

  • Stock Ratings: Citi maintains a neutral rating with a AU$1.05 price target, while Jefferies raises its target from AU$1.45 to AU$1.65 but retains a hold rating.

Australian healthcare services company Healius (ASX:HLS) has announced an ambitious EBIT margin target for FY27, aiming for a high single-digit percentage. This projection exceeds analyst expectations from both Citi and Jefferies, sparking mixed reactions from the market.

Analysts Take a Cautious Stance

While the target suggests potential earnings uplift, Citi warns that investors may approach this projection with skepticism due to Healius' history of missed expectations and relatively high valuation.

Jefferies acknowledges the growth potential in the Australian healthcare sector and believes Healius could capitalise on emerging opportunities. However, the firm will wait for tangible progress toward these goals before adjusting its forecasts.

Stock Performance and Ratings

Despite lingering doubts, Healius' stock has gained 5.8% year-to-date. Citi has kept its neutral rating with a AU$1.05 target price, while Jefferies has upgraded its price target from AU$1.45 to AU$1.65, maintaining a hold recommendation.

With analysts divided, the focus now shifts to whether Healius can deliver on its targets and sustain investor confidence in the coming years.